Panel
Iniciar SesiónRegistrarse

Noticias Financieras

Why XRP Retail Holders Are Positioned Ahead Of Institutional Adoption
newsbtchace 137d

Why XRP Retail Holders Are Positioned Ahead Of Institutional Adoption

XRP has been misunderstood as just another retail-traded crypto asset, when in reality, it was engineered from the ground up to serve institutional finance. Most retail investors approach XRP through the lens of short-term price action, but that framing misses what the asset was actually built to do. XRP was never built for retail investors. Crypto trader Adam highlighted on X that from the outset, XRP was designed as institutional-grade infrastructure, powering liquidity corridors, cross-border settlements, and the movement of value between financial systems fast and efficiently. How Early Liquidity Providers Sit Ahead Of Demand The goal isn’t hype or speculation, but rather plumbing for global money flow. In this framework, the retail participant isn’t the target audience. Instead, retail holders occupy an early position, providing optional liquidity and gaining front-row access while the underlying rails are still being built. Related Reading: Ripple’s Next Steps: Where XRP Stops Being Trade And Starts Being Infrastrucutre As institutional adoption continues to expand, retail holders are positioned ahead of the curve and may benefit from utility demand, which ultimately drives long-term value. In this contest, being early doesn’t mean being excluded; it simply means being advantaged ahead of the curve. XRP has already transitioned into an institutional-grade asset. Analyst Xfinancebull has pointed out that the narrative from just two years ago was that many believed institutions would avoid XRP due to its uncertainty, perceived risk, and regulatory clarity, but that landscape has shifted. Currently, XRP exposure is available on major institutional platforms, including Vanguard, which manages over $10 trillion in assets and serves more than 50 million investors globally, and is second only to BlackRock. Multiple XRP ETFs are now live and accessible, including the Bitwise XRP ETF, Franklin Templeton XRP ETF, Canary XRP ETF, and Teucrium 2x XRP ETF. Despite this progress, XRP’s price remains low, and institutions are not emotional about the dip because they don’t buy green candles; they accumulate during the times of fear, and position their capital when retail interest is distracted or discouraged. XRP is now available on the same platforms used in managing retirement funds for millions of Americans and now offers direct XRP exposure. Once institutional allocations begin to flow, available supply can be absorbed quickly. “You’re either positioned before institutions move, or chasing after they’ve already entered,” Xfinancebull noted. Banks Are Already Testing XRPL Infrastructure According to Jake Claver, the CEO of DAGFamilyOffice, the global banking system currently has roughly $27 trillion locked in pre-funded accounts, which only exist because banks can’t settle transactions in real-time. Meanwhile, the XRP ledger alternative can handle that settlement in seconds, and banks are already testing this infrastructure. Related Reading: XRP Tops All Assets On Risk/Reward, Analyst Says The key question, as Claver frames it, is not whether real-time settlement is possible, but how long the current system can persist before the efficiency gains become impossible for banks to ignore. Featured image from Freepik, chart from Tradingview.com

#TECH
Govt Sets Up 100 5G Labs in Institutions to Foster AI, Blockchain
newsable_asianetnewshace 137d

Govt Sets Up 100 5G Labs in Institutions to Foster AI, Blockchain

The government has established 100 5G Use Case Labs in educational institutions to promote app development with AI and blockchain. This initiative aims to foster innovation and academia-industry collaboration for the nation's digital growth.

#TECH
India-US advance defence science, tech cooperation at DRDO meet
newsable_asianetnewshace 137d

India-US advance defence science, tech cooperation at DRDO meet

India and the US held the 24th Joint Technical Group Plenary at DRDO HQ in New Delhi to boost defence science and technology cooperation. Delegations reviewed ongoing projects, discussed challenges, and explored strengthening collaboration.

#TECH
thedailystarhace 137d

Bitcoin plunges below $70,000

Bitcoin, the world’s biggest cryptocurrency, extended its price slump Thursday to trade under $70,000 for the first time since Donald Trump’s presidential election victory in November 2024.

#CRYPTO
Sydney now rivals New York, tops London, for mega property deals
realestatehace 137d

Sydney now rivals New York, tops London, for mega property deals

Sydney has surged past London and drawn level with New York in a global wealth list after the city’s rich went on a $3.3 billion spending spree last year.The post Sydney now rivals New York, tops London, for mega property deals appeared first on realestate.com.au.

#STOCKS
Why Novo Nordisk stock fell 7% after a telehealth startup’s announcement
fastcompanyhace 137d

Why Novo Nordisk stock fell 7% after a telehealth startup’s announcement

Novo Nordisk’s stock dove 7% on Thursday just after an announcement from a key competitor.The drop came just after telehealth company Hims & Hers announced it will offer a new version of the treatment, made from the same active ingredient, semaglutide, for a fraction of Novo Nordisk’s price. The telehealth site will offer the treatment at an introductory price of $49, the announcement said. After the introductory offer ends, patients with a 5-month subscription will pay $99 monthly for the treatment. Novo Nordisk sells the weight-loss drug for $149. Hims & Hers had already been offering the treatment in an injectable form, but the oral version is new for the brand. “We’re excited to find ways to continue bringing branded treatments to the platform across specialties. More choice on the platform is the best thing for customers everywhere,” said Hims CEO Andrew Dudum in a statement.While the announcement spurred Novo Nordisk’s stock to reach its lowest level since July 2021, it wasn’t the only company that saw its stock slip on Thursday. Eli Lilly’s fell by up to 6.1% on the announcement. Meanwhile, Hims and Hers Health stock surged 19% on Thursday.On Wednesday, Novo CFO Karsten Munk Knudsen told Reuters that the company is “frustrated” with “mass marketing” of knock-off versions of the drug which was “unapproved by the FDA”. The CFO warned that unprecedented pricing pressure as competition grows in the weight-loss drug market, added that it’s a challenge to predict “if and when the tide turns” for the brand.Per Hims & Hers announcement, the company said that safety is the brand’s “top priority.” It continued, “The Compounded Semaglutide Pill joins a wide range of other weight loss treatments accessible through our platform, all of which meet rigorous clinical standards.”Fast Company reached out to Novo Nordisk but did not hear back by the time of publication.In November, when the company dropped its prices to fend off competition, Dave Moore, executive vice president of U.S. operations at Novo Nordisk, said, “As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them.”Moore continued: “The U.S. healthcare system is complex, with different types of insurance and various ways for patients to obtain their medicines. Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay.”

#STOCKS